|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: BTNL9 |
Gene summary for BTNL9 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | BTNL9 | Gene ID | 153579 |
| Gene name | butyrophilin like 9 | |
| Gene Alias | BTN3 | |
| Cytomap | 5q35.3 | |
| Gene Type | protein-coding | GO ID | GO:0001816 | UniProtAcc | Q6UXG8 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 153579 | BTNL9 | C38 | Human | Oral cavity | OSCC | 1.12e-18 | 1.40e+00 | 0.172 |
| 153579 | BTNL9 | C43 | Human | Oral cavity | OSCC | 6.35e-26 | 4.54e-01 | 0.1704 |
| 153579 | BTNL9 | C46 | Human | Oral cavity | OSCC | 2.77e-43 | 9.00e-01 | 0.1673 |
| 153579 | BTNL9 | LN38 | Human | Oral cavity | OSCC | 2.78e-08 | 8.96e-01 | 0.168 |
| 153579 | BTNL9 | LN46 | Human | Oral cavity | OSCC | 3.26e-50 | 1.58e+00 | 0.1666 |
| 153579 | BTNL9 | SYSMH1 | Human | Oral cavity | OSCC | 7.87e-03 | 9.95e-02 | 0.1127 |
| 153579 | BTNL9 | SYSMH3 | Human | Oral cavity | OSCC | 4.24e-06 | 1.47e-01 | 0.2442 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00508527 | Oral cavity | OSCC | T cell receptor signaling pathway | 68/7305 | 123/18723 | 1.80e-04 | 1.22e-03 | 68 |
| GO:00027646 | Oral cavity | OSCC | immune response-regulating signaling pathway | 212/7305 | 468/18723 | 2.93e-03 | 1.27e-02 | 212 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| BTNL9 | SNV | Missense_Mutation | novel | c.77N>C | p.Leu26Pro | p.L26P | Q6UXG8 | protein_coding | deleterious(0.01) | possibly_damaging(0.819) | TCGA-4R-AA8I-01 | Liver | liver hepatocellular carcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
| BTNL9 | SNV | Missense_Mutation | novel | c.478N>A | p.Ser160Thr | p.S160T | Q6UXG8 | protein_coding | deleterious(0.05) | benign(0.044) | TCGA-49-AAR4-01 | Lung | lung adenocarcinoma | Male | <65 | III/IV | Chemotherapy | taxol | PD |
| BTNL9 | SNV | Missense_Mutation | c.553C>A | p.Gln185Lys | p.Q185K | Q6UXG8 | protein_coding | deleterious(0.05) | possibly_damaging(0.54) | TCGA-49-AAR9-01 | Lung | lung adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | PD | |
| BTNL9 | SNV | Missense_Mutation | c.693N>A | p.Asn231Lys | p.N231K | Q6UXG8 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-73-4677-01 | Lung | lung adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD | |
| BTNL9 | SNV | Missense_Mutation | rs146697971 | c.937C>T | p.Arg313Trp | p.R313W | Q6UXG8 | protein_coding | deleterious(0) | probably_damaging(0.973) | TCGA-86-8669-01 | Lung | lung adenocarcinoma | Male | <65 | I/II | Chemotherapy | cisplatin | CR |
| BTNL9 | SNV | Missense_Mutation | c.1466N>T | p.Arg489Met | p.R489M | Q6UXG8 | protein_coding | tolerated(0.06) | probably_damaging(0.95) | TCGA-95-A4VK-01 | Lung | lung adenocarcinoma | Female | >=65 | III/IV | Chemotherapy | cisplatin | PD | |
| BTNL9 | SNV | Missense_Mutation | c.1315N>T | p.Ala439Ser | p.A439S | Q6UXG8 | protein_coding | tolerated(0.45) | benign(0.051) | TCGA-34-5927-01 | Lung | lung squamous cell carcinoma | Female | >=65 | I/II | Chemotherapy | carboplatin | SD | |
| BTNL9 | SNV | Missense_Mutation | novel | c.1300N>T | p.Ala434Ser | p.A434S | Q6UXG8 | protein_coding | tolerated(0.54) | benign(0.029) | TCGA-39-5034-01 | Lung | lung squamous cell carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
| BTNL9 | SNV | Missense_Mutation | novel | c.111N>T | p.Glu37Asp | p.E37D | Q6UXG8 | protein_coding | deleterious(0.04) | benign(0.042) | TCGA-60-2724-01 | Lung | lung squamous cell carcinoma | Male | <65 | III/IV | Chemotherapy | cisplatin | SD |
| BTNL9 | deletion | Frame_Shift_Del | c.123delA | p.Gly42AlafsTer109 | p.G42Afs*109 | Q6UXG8 | protein_coding | TCGA-4B-A93V-01 | Lung | lung adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
| Page: 1 2 3 4 5 6 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |